Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00723723 |
Recruitment Status :
Completed
First Posted : July 29, 2008
Last Update Posted : August 13, 2015
|
Sponsor:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.
Condition or disease | Intervention/treatment |
---|---|
Coronary Heart Disease Hypercholesterolemia Hyperlipidemia | Drug: Statin |
Study Type : | Observational |
Actual Enrollment : | 555 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Compliance With LDL-Lowering Therapy For Secondary Prevention of Coronary Heart Disease in Real Life Practice |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | June 2009 |
Resource links provided by the National Library of Medicine

Group/Cohort | Intervention/treatment |
---|---|
Patients with coronary heart disease
Patients being treated with a statin for secondary prevention of coronary heart disease
|
Drug: Statin
Statin |
Primary Outcome Measures :
- percentage of patients reaching target LDL levels [ Time Frame: 6-8 weeks after first visit and 28-32 weeks after first visit ]
Secondary Outcome Measures :
- measure patient compliance to treatment as assessed by counting returned tablets [ Time Frame: 6-8 weeks after first visit and 28-32 weeks after first visit ]
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Study Population
Patients being treated with a statin for secondary prevention of coronary heart disease
Criteria
Inclusion Criteria:
- willingness to participate in the study
- 18 years of age or more
- clinically established cardiovascular disease to be considered as patients in secondary prevention
- prior therapy with any statin without achieving goal (2.5 mmol/L of LDL cholesterol) at last lipid check performed
Exclusion Criteria:
- None
No Contacts or Locations Provided
Responsible Party: | Merck Sharp & Dohme Corp. |
ClinicalTrials.gov Identifier: | NCT00723723 |
Other Study ID Numbers: |
P05467 |
First Posted: | July 29, 2008 Key Record Dates |
Last Update Posted: | August 13, 2015 |
Last Verified: | August 2015 |
Additional relevant MeSH terms:
Heart Diseases Coronary Disease Coronary Artery Disease Myocardial Ischemia Hypercholesterolemia Hyperlipidemias Cardiovascular Diseases |
Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases |